First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers
Abstract HDIT101 is a first‐in‐class humanized monoclonal antibody recognizing a conserved epitope in glycoprotein B, a target present on the surface of herpes simplex virus 1 (HSV‐1) and HSV‐2 particles as well as on virus‐infected cells. This was a first‐in‐human, single‐center, double‐blind, plac...
Furkejuvvon:
Váldodahkkit: | , , , , , , , , , , , , , , , |
---|---|
Materiálatiipa: | Girji |
Almmustuhtton: |
Wiley,
2022-10-01T00:00:00Z.
|
Fáttát: | |
Liŋkkat: | Connect to this object online. |
Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Interneahtta
Connect to this object online.3rd Floor Main Library
Hildobáiki: |
A1234.567 |
---|---|
Njađus 1 | Oažžumis |